VRTX Vertex Pharmaceuticals
Nasdaq · SEC CIK 875320 · EDGAR
- Bought, last 12 months
- $0 0 purchases by 0 insiders
- Sold, last 12 months
- $158.38M 53 sales by 13 insiders
- Filings on record
- 531 since 2021-07-16, latest 2026-09-10 16:31
BoughtSold
Most active insiders, 12 months
| Insider | Title | Bought | Sold |
|---|---|---|---|
| LEIDEN JEFFREY M | Executive COB, Dir | — | $60.94M |
| Sachdev Amit | EVP Chief Patient, Ext Af Off | — | $28.38M |
| Kewalramani Reshma | CEO, Pres, Dir | — | $19.74M |
| Bozic Carmen | EVP, CMO | — | $11.31M |
| WAGNER CHARLES F JR | EVP, CO, FO | — | $10.78M |
| Tatsis Ourania | EVP, Chief Reg, Quality Off | — | $6.51M |
| McKechnie Duncan | EVP, Chief Commercial Off | — | $5.66M |
| Biller Jonathan | EVP, CLO | — | $4.08M |
| Atkinson Edward Morrow III | EVP, Chief Technical Ops. Off | — | $3.60M |
| Bunnage Mark E. | EVP, CSO | — | $3.00M |
Transactions 621
| X | Filed | Traded | Ticker | Insider | Title | Type | Price | Qty | Owned | ΔOwn | Value |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 2024-02-23 | 2024-02-21 | VRTX | Atkinson Edward Morrow III | EVP, Chief Technical Ops. Off | S - Sale | $421.77 | -1,201 | 18.5K | -6% | -$506.5K | |
| 2024-02-23 | 2024-02-21 | VRTX | Tatsis Ourania | EVP, Chief Reg, Quality Off | S - Sale | $421.77 | -360 | 59.5K | -0.6% | -$151.8K | |
| 2024-02-23 | 2024-02-21 | VRTX | Arbuckle Stuart A | EVP, COO | S - Sale | $421.77 | -3,603 | 59.4K | -6% | -$1.52M | |
| M | 2024-02-21 | 2024-02-16+ | VRTX | Atkinson Edward Morrow III | EVP, Chief Technical Ops. Off | F - Tax | $422.54 | -2,626 | 21.6K | -11% | -$1.11M |
| 2024-02-21 | 2024-02-20 | VRTX | Atkinson Edward Morrow III | EVP, Chief Technical Ops. Off | S - Sale | $420.79 | -801 | 19.7K | -4% | -$337.1K | |
| 2024-02-21 | 2024-02-20 | VRTX | Sachdev Amit | EVP Chief Patient, Ext Af Off | S - Sale | $420.79 | -4,254 | 64.0K | -6% | -$1.79M | |
| M | 2024-02-21 | 2024-02-16+ | VRTX | Sachdev Amit | EVP Chief Patient, Ext Af Off | F - Tax | $422.54 | -6,121 | 70.9K | -8% | -$2.59M |
| M | 2024-02-21 | 2024-02-16+ | VRTX | ALTSHULER DAVID | EVP, CSO, Gbl Research | F - Tax | $422.54 | -6,562 | 43.8K | -13% | -$2.77M |
| 2024-02-21 | 2024-02-20 | VRTX | ALTSHULER DAVID | EVP, CSO, Gbl Research | S - Sale | $420.79 | -4,002 | 37.0K | -10% | -$1.68M | |
| 2024-02-21 | 2024-02-20 | VRTX | Arbuckle Stuart A | EVP, COO | S - Sale | $420.79 | -4,804 | 63.0K | -7% | -$2.02M | |
| M | 2024-02-21 | 2024-02-16+ | VRTX | Arbuckle Stuart A | EVP, COO | F - Tax | $422.54 | -7,872 | 67.8K | -10% | -$3.33M |
| 2024-02-21 | 2024-02-20 | VRTX | LEIDEN JEFFREY M | Executive COB, Dir | F - Tax | $420.58 | -4,118 | 13.8K | -23% | -$1.73M | |
| M | 2024-02-21 | 2024-02-16+ | VRTX | WAGNER CHARLES F JR | EVP, CFO | F - Tax | $422.54 | -6,562 | 56.9K | -10% | -$2.77M |
| M | 2024-02-21 | 2024-02-16+ | VRTX | Tatsis Ourania | EVP, Chief Reg, Quality Off | F - Tax | $422.54 | -7,872 | 60.3K | -12% | -$3.33M |
| 2024-02-21 | 2024-02-20 | VRTX | Tatsis Ourania | EVP, Chief Reg, Quality Off | S - Sale | $420.79 | -480 | 59.8K | -0.8% | -$202.0K | |
| M | 2024-02-21 | 2024-02-16+ | VRTX | Bozic Carmen | EVP, CMO | F - Tax | $422.54 | -6,562 | 40.2K | -14% | -$2.77M |
| M | 2024-02-21 | 2024-02-16+ | VRTX | Kewalramani Reshma | CEO, Pres, Dir | F - Tax | $422.54 | -16.4K | 145.9K | -10% | -$6.92M |
| M | 2024-02-16 | 2024-02-14+ | VRTX | LEIDEN JEFFREY M | Executive COB, Dir | S - Sale | $419.10 | -9,011 | 17.9K | -33% | -$3.78M |
| M | 2024-02-14 | 2024-02-12+ | VRTX | LEIDEN JEFFREY M | Executive COB, Dir | S - Sale | $419.42 | -3,393 | 28.3K | -11% | -$1.42M |
| 2024-02-13 | 2024-02-09 | VRTX | Ambrose Kristen | SVP, CAO | F - Tax | $422.74 | -591 | 11.1K | -5% | -$249.8K | |
| 2024-02-13 | 2024-02-12 | VRTX | Ambrose Kristen | SVP, CAO | S - Sale | $420.24 | -1,374 | 9,676 | -12% | -$577.4K | |
| 2024-02-13 | 2024-02-12 | VRTX | Arbuckle Stuart A | EVP, COO | S - Sale | $420.24 | -4,295 | 75.7K | -5% | -$1.80M | |
| 2024-02-13 | 2024-02-09 | VRTX | Arbuckle Stuart A | EVP, COO | F - Tax | $422.74 | -3,177 | 80.0K | -4% | -$1.34M | |
| 2024-02-13 | 2024-02-09 | VRTX | Kewalramani Reshma | CEO, Pres, Dir | F - Tax | $422.74 | -8,255 | 162.3K | -5% | -$3.49M | |
| 2024-02-13 | 2024-02-12 | VRTX | Atkinson Edward Morrow III | EVP, Chief Technical Ops. Off | S - Sale | $420.24 | -913 | 23.1K | -4% | -$383.7K | |
| 2024-02-13 | 2024-02-09 | VRTX | Atkinson Edward Morrow III | EVP, Chief Technical Ops. Off | F - Tax | $422.74 | -832 | 24.1K | -3% | -$351.7K | |
| 2024-02-13 | 2024-02-12 | VRTX | ALTSHULER DAVID | EVP, CSO, Gbl Research | S - Sale | $420.24 | -3,145 | 47.6K | -6% | -$1.32M | |
| 2024-02-13 | 2024-02-09 | VRTX | ALTSHULER DAVID | EVP, CSO, Gbl Research | F - Tax | $422.74 | -2,099 | 50.7K | -4% | -$887.3K | |
| 2024-02-13 | 2024-02-09 | VRTX | WAGNER CHARLES F JR | EVP, CFO | F - Tax | $422.74 | -2,607 | 63.5K | -4% | -$1.10M | |
| 2024-02-13 | 2024-02-09 | VRTX | Bozic Carmen | EVP, CMO | F - Tax | $422.74 | -2,100 | 46.8K | -4% | -$887.8K | |
| 2024-02-13 | 2024-02-12 | VRTX | Tatsis Ourania | EVP, Chief Reg, Quality Off | S - Sale | $420.24 | -314 | 68.2K | -0.5% | -$132.0K | |
| 2024-02-13 | 2024-02-09 | VRTX | Tatsis Ourania | EVP, Chief Reg, Quality Off | F - Tax | $422.74 | -2,100 | 68.5K | -3% | -$887.8K | |
| 2024-02-13 | 2024-02-09 | VRTX | Biller Jonathan | EVP, CLO | F - Tax | $422.74 | -1,588 | 20.0K | -7% | -$671.3K | |
| 2024-02-13 | 2024-02-12 | VRTX | Biller Jonathan | EVP, CLO | S - Sale | $418.77 | -1,738 | 18.3K | -9% | -$727.8K | |
| 2024-02-13 | 2024-02-12 | VRTX | Sachdev Amit | EVP Chief Patient, Ext Af Off | S - Sale | $420.24 | -3,222 | 74.4K | -4% | -$1.35M | |
| 2024-02-13 | 2024-02-09 | VRTX | Sachdev Amit | EVP Chief Patient, Ext Af Off | F - Tax | $422.74 | -2,022 | 77.6K | -3% | -$854.8K | |
| M | 2024-02-12 | 2024-02-08+ | VRTX | LEIDEN JEFFREY M | Executive COB, Dir | F - Tax | $422.49 | -10.7K | 30.3K | -26% | -$4.54M |
| M | 2024-02-08 | 2024-02-06+ | VRTX | Bozic Carmen | EVP, CMO | A - Grant | $0.00 | +19.6K | 48.9K | +67% | $0 |
| M | 2024-02-08 | 2024-02-06+ | VRTX | LEIDEN JEFFREY M | Executive COB, Dir | A - Grant | $0.00 | +38.6K | 41.0K | +1,594% | $0 |
| M | 2024-02-08 | 2024-02-06+ | VRTX | Atkinson Edward Morrow III | EVP, Chief Technical Ops. Off | A - Grant | $0.00 | +11.0K | 20.1K | +120% | $0 |
| M | 2024-02-08 | 2024-02-06+ | VRTX | WAGNER CHARLES F JR | EVP, CFO | A - Grant | $0.00 | +22.4K | 58.9K | +61% | $0 |
| M | 2024-02-08 | 2024-02-06+ | VRTX | Biller Jonathan | EVP, CLO | A - Grant | $0.00 | +11.0K | 16.9K | +189% | $0 |
| M | 2024-02-08 | 2024-02-06+ | VRTX | ALTSHULER DAVID | EVP, CSO, Gbl Research | A - Grant | $0.00 | +20.8K | 52.8K | +65% | $0 |
| M | 2024-02-08 | 2024-02-06+ | VRTX | Ambrose Kristen | SVP, CAO | A - Grant | $0.00 | +4,803 | 9,788 | +96% | $0 |
| M | 2024-02-08 | 2024-02-06+ | VRTX | Tatsis Ourania | EVP, Chief Reg, Quality Off | A - Grant | $0.00 | +22.0K | 70.6K | +45% | $0 |
| M | 2024-02-08 | 2024-02-06+ | VRTX | Kewalramani Reshma | CEO, Pres, Dir | A - Grant | $0.00 | +61.8K | 123.2K | +101% | $0 |
| M | 2024-02-08 | 2024-02-06+ | VRTX | Arbuckle Stuart A | EVP, COO | A - Grant | $0.00 | +26.6K | 74.7K | +55% | $0 |
| M | 2024-02-08 | 2024-02-06+ | VRTX | Sachdev Amit | EVP Chief Patient, Ext Af Off | A - Grant | $0.00 | +20.8K | 64.6K | +47% | $0 |
| 2024-01-10 | 2024-01-08 | VRTX | LEIDEN JEFFREY M | Executive COB, Dir | S - Sale | $419.07 | -6,648 | 2,423 | -73% | -$2.79M | |
| 2024-01-04 | 2024-01-02 | VRTX | WAGNER CHARLES F JR | EVP, CFO | S - Sale | $405.00 | -3,000 | 43.7K | -6% | -$1.22M | |
| DM | 2023-12-19 | 2023-12-15 | VRTX | Kewalramani Reshma | CEO, Pres, Dir | M - OptEx | $181.83 | +17.1K | 111.8K | +18% | +$3.12M |
| D | 2023-12-19 | 2023-12-15 | VRTX | Kewalramani Reshma | CEO, Pres, Dir | S - Sale+OE | $407.00 | -17.1K | 108.7K | -14% | -$6.97M |
| 2023-12-15 | 2023-12-13 | VRTX | Kewalramani Reshma | CEO, Pres, Dir | S - Sale | $397.00 | -5,098 | 108.7K | -4% | -$2.02M | |
| D | 2023-12-15 | 2023-12-13 | VRTX | Arbuckle Stuart A | EVP, COO | M - OptEx | $187.53 | +8,603 | 65.2K | +15% | +$1.61M |
| D | 2023-12-15 | 2023-12-13 | VRTX | Arbuckle Stuart A | EVP, COO | S - Sale+OE | $399.00 | -8,603 | 56.6K | -13% | -$3.43M |
| M | 2023-12-15 | 2023-12-13 | VRTX | LEIDEN JEFFREY M | Executive COB, Dir | S - Sale | $399.42 | -13.4K | 9,171 | -59% | -$5.33M |
| 2023-12-06 | 2023-12-05 | VRTX | Thornberry Nancy | Dir | A - Grant | $0.00 | +1,136 | 1,136 | New | $0 | |
| 2023-11-21 | 2023-11-20 | VRTX | WAGNER CHARLES F JR | EVP, CFO | S - Sale | $349.88 | -3,000 | 46.7K | -6% | -$1.05M | |
| 2023-11-17 | 2023-11-15 | VRTX | ALTSHULER DAVID | EVP, CSO, Gbl Research | S - Sale | $369.92 | -19 | 32.0K | -0.1% | -$7,028 | |
| 2023-11-17 | 2023-11-15 | VRTX | Sachdev Amit | EVP Chief Patient, Ext Af Off | S - Sale | $369.92 | -35 | 58.8K | -0.1% | -$12.9K | |
| 2023-11-16 | 2023-11-14 | VRTX | Bozic Carmen | EVP, CMO | S - Sale | $380.82 | -5,650 | 29.3K | -16% | -$2.15M | |
| 2023-11-15 | 2023-11-13 | VRTX | Kewalramani Reshma | CEO, Pres, Dir | S - Sale | $377.00 | -5,097 | 113.8K | -4% | -$1.92M | |
| D | 2023-11-08 | 2023-11-06 | VRTX | SACHS BRUCE I | Dir | S - Sale+OE | $385.00 | -11.2K | 40.0K | -22% | -$4.33M |
| D | 2023-11-08 | 2023-11-06 | VRTX | SACHS BRUCE I | Dir | M - OptEx | $127.54 | +11.2K | 51.2K | +28% | +$1.43M |
| 2023-11-02 | 2023-10-31 | VRTX | Bozic Carmen | EVP, CMO | S - Sale | $355.92 | -5,651 | 35.0K | -14% | -$2.01M | |
| 2023-10-19 | 2023-10-17 | VRTX | Bhatia Sangeeta N. | Dir | S - Sale | $375.00 | -243 | 3,901 | -6% | -$91.1K | |
| 2023-10-19 | 2023-10-17 | VRTX | Bozic Carmen | EVP, CMO | S - Sale | $373.25 | -5,651 | 40.6K | -12% | -$2.11M | |
| 2023-10-18 | 2023-10-16 | VRTX | LEIDEN JEFFREY M | Executive COB, Dir | S - Sale | $374.00 | -13.0K | 22.4K | -37% | -$4.85M | |
| 2023-10-11 | 2023-10-06 | VRTX | Bhatia Sangeeta N. | Dir | S - Sale | $360.00 | -242 | 4,144 | -6% | -$87.1K | |
| 2023-10-10 | 2023-10-05 | VRTX | Lagarde Michel | Dir | A - Grant | $0.00 | +1,132 | 1,132 | New | $0 | |
| 2023-10-05 | 2023-10-03 | VRTX | Bozic Carmen | EVP, CMO | S - Sale | $345.28 | -5,651 | 46.3K | -11% | -$1.95M | |
| 2023-10-03 | 2023-09-29 | VRTX | Biller Jonathan | EVP, CLO | F - Tax | $350.72 | -408 | 11.2K | -4% | -$143.1K | |
| 2023-10-03 | 2023-10-02 | VRTX | Biller Jonathan | EVP, CLO | S - Sale | $346.76 | -610 | 10.6K | -5% | -$211.5K | |
| 2023-09-21 | 2023-09-19 | VRTX | Bozic Carmen | EVP, CMO | S - Sale | $351.00 | -5,651 | 51.9K | -10% | -$1.98M | |
| 2023-09-07 | 2023-09-05 | VRTX | Bozic Carmen | EVP, CMO | S - Sale | $352.66 | -5,651 | 57.6K | -9% | -$1.99M | |
| 2023-08-25 | 2023-08-23 | VRTX | Tatsis Ourania | EVP, Chief Reg, Quality Off | S - Sale | $355.00 | -2,500 | 48.6K | -5% | -$887.5K | |
| 2023-08-14 | 2023-08-10 | VRTX | Tatsis Ourania | EVP, Chief Reg, Quality Off | S - Sale | $345.79 | -5,750 | 51.1K | -10% | -$1.99M | |
| D | 2023-08-14 | 2023-08-10 | VRTX | Kearney Terrence C | Dir | M - OptEx | $127.54 | +10.0K | 16.5K | +153% | +$1.28M |
| D | 2023-08-14 | 2023-08-10 | VRTX | Kearney Terrence C | Dir | S - Sale+OE | $350.00 | -10.0K | 6,536 | -60% | -$3.50M |
| 2023-08-14 | 2023-08-10 | VRTX | Sachdev Amit | EVP, Chief Patient Off | S - Sale | $350.00 | -10.0K | 58.8K | -15% | -$3.51M | |
| 2023-08-11 | 2023-08-09 | VRTX | ALTSHULER DAVID | EVP, CSO, Gbl Research | S - Sale | $345.51 | -63 | 32.0K | -0.2% | -$21.8K | |
| 2023-08-11 | 2023-08-09 | VRTX | Bhatia Sangeeta N. | Dir | S - Sale | $345.51 | -242 | 4,386 | -5% | -$83.6K | |
| 2023-07-18 | 2023-07-17 | VRTX | Kewalramani Reshma | CEO, Pres, Dir | S - Sale | $355.00 | -7,828 | 118.9K | -6% | -$2.78M | |
| DM | 2023-07-18 | 2023-07-17 | VRTX | SACHS BRUCE I | Dir | S - Sale+OE | $356.75 | -11.2K | 49.6K | -19% | -$4.01M |
| D | 2023-07-18 | 2023-07-17 | VRTX | SACHS BRUCE I | Dir | M - OptEx | $127.54 | +11.2K | 51.2K | +28% | +$1.43M |
| D | 2023-06-20 | 2023-06-15 | VRTX | Arbuckle Stuart A | EVP, COO | M - OptEx | $187.53 | +8,603 | 65.2K | +15% | +$1.61M |
| D | 2023-06-20 | 2023-06-15 | VRTX | Arbuckle Stuart A | EVP, COO | S - Sale+OE | $349.00 | -8,603 | 56.6K | -13% | -$3.00M |
| 2023-06-01 | 2023-05-30 | VRTX | Arbuckle Stuart A | EVP, COO | S - Sale | $329.82 | -82 | 56.6K | -0.1% | -$27.0K | |
| 2023-06-01 | 2023-05-30 | VRTX | Ambrose Kristen | SVP, CAO | S - Sale | $329.82 | -289 | 6,838 | -4% | -$95.3K | |
| M | 2023-05-09 | 2023-05-05+ | VRTX | LEIDEN JEFFREY M | Executive COB, Dir | S - Sale | $349.25 | -2,004 | 36.7K | -5% | -$699.9K |
| M | 2023-05-09 | 2023-05-05+ | VRTX | Sanna Bastiano | EVP, Cell, Genetic Therapies | S - Sale | $350.00 | -3,272 | 34.9K | -9% | -$1.15M |
| M | 2023-05-04 | 2023-05-02+ | VRTX | LEIDEN JEFFREY M | Executive COB, Dir | S - Sale | $349.98 | -11.0K | 37.4K | -23% | -$3.84M |
| M | 2023-05-04 | 2023-05-02+ | VRTX | Sanna Bastiano | EVP, Cell, Genetic Therapies | S - Sale | $350.71 | -4,403 | 35.3K | -11% | -$1.54M |
| 2023-05-03 | 2023-05-01 | VRTX | CARNEY LLOYD | Dir | A - Grant | $0.00 | +1,168 | 5,318 | +28% | $0 | |
| D | 2023-05-03 | 2023-05-01 | VRTX | MCKENZIE DIANA | Dir | A - Grant | $0.00 | +1,168 | 2,603 | +81% | $0 |
| D | 2023-05-03 | 2023-05-01 | VRTX | MCKENZIE DIANA | Dir | D - Sale to Iss | — | -1,449 | 1,435 | -50% | — |
| D | 2023-05-03 | 2023-05-01 | VRTX | Garber Alan M | Dir | A - Grant | $0.00 | +584 | 6,474 | +10% | $0 |
| 2023-05-03 | 2023-05-01 | VRTX | Upadhyay Suketu | Dir | A - Grant | $0.00 | +1,168 | 2,726 | +75% | $0 | |
| M | 2023-05-03 | 2023-05-02 | VRTX | Bhatia Sangeeta N. | Dir | S - Sale | $348.28 | -580 | 4,691 | -11% | -$202.0K |
| 2023-05-03 | 2023-05-01 | VRTX | Bhatia Sangeeta N. | Dir | A - Grant | $0.00 | +1,168 | 5,208 | +29% | $0 |
Purchase Sale Sale after option exercise All abbreviations